Expert Opinion on Therapeutic Targets

Target validation and functional analyses using antisense oligonucleotides
pp. 297-301(5)
Author: Taylor M.F.

Chemokine receptors: emerging opportunities for new anti-HIV therapies
pp. 303-326(24)
Authors: Agrawal L.; Alkhatib G.

The Type III secretion system of Gram-negative bacteria: a potential therapeutic target?
pp. 327-339(13)
Authors: Müller S.; Feldman M.F.; Cornelis G.R.

Human -secretase and Alzheimer’s disease
pp. 341-348(8)
Author: Citron M.

Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs
pp. 349-362(14)
Authors: Di Marzo V.; Bisogno T.; Petrocellis L.D.

Telomerase - strategies to exploit an important chemotherapeutic target
pp. 363-378(16)
Author: Fletcher T.M.

Mechanisms of MHC class I-restricted antigen presentation
pp. 379-393(15)
Authors: Hofmann M.; Nussbaum A.K.; Emmerich N.P.; Stoltze L.; Schild H.

Emerging molecular targets for the treatment of pre-eclampsia
pp. 395-413(19)
Authors: Page N.M.; Kemp C.F.; Lowry P.J.

Resistance to anti-peptide deformylase drugs
pp. 415-418(4)
Authors: Giglione C.; Meinnel T.